TABLE 1.
Treatmenta | Tumor class (%) |
||||||
Incidence (%) | HCA | HCC | MA | MC | CCA | CCC | |
Initiated at 10 weeks | |||||||
Sham/CON | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sham/E2 | 7* | 0 | 58 | 0 | 33 | 8 | 0 |
Sham/PFOA | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sham/PFNA | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sham/PFDA | 5 | 0 | 0 | 0 | 100 | 0 | 0 |
Sham/FtOH | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sham/CLOF | 1 | 0 | 0 | 0 | 100 | 0 | 0 |
AFB1/CON | 13 | 26 | 23 | 2 | 47 | 0 | 2 |
AFB1/E2 | 83#### | 6 | 22 | 4 | 65 | 1 | 2 |
AFB1/PFOA | 62## | 10 | 27 | 1 | 54 | 4 | 5 |
AFB1/PFNA | 72#### | 5 | 17 | 0 | 68 | 3 | 8 |
AFB1/PFDA | 88#### | 7 | 24 | 1 | 63 | 1 | 4 |
AFB1/FtOH | 23 | 12 | 29 | 3 | 52 | 2 | 2 |
AFB1/CLOF | 15 | 11 | 29 | 6 | 41 | 5 | 8 |
Initiated at 15 weeks | |||||||
Sham/CON | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sham/PFOS | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AFB1/CON | 1 | 0 | 29 | 0 | 71 | 0 | 0 |
AFB1/PFOS | 13†† | 5 | 10 | 5 | 68 | 3 | 10 |
Note. CCA, cholangiocellular adenoma; CCC, cholangiocellular carcinoma; HCA, hepatocellular adenoma; HCC, hepatocellular carcinoma; MA, mixed adenoma; MC, mixed carcinoma.
Treatment groups are indicated as initiation/diet (see “Materials and Methods” section for complete details.
p < 0.05 compared with Sham/CON; ##p < 0.01; ####p < 0.0001 compared with AFB1/CON; ††p < 0.01 compared with AFB1/CON (15 weeks) as determined by logistic regression analysis.